The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. This is the first four drug combination treatment approved for lung cancer. Click here to learn more.
Tuesday, October 30, 2018 – Today the Food and Drug Administration (FDA) approved immunotherapy drug, pembrolizumab, also known as KEYTRUDA, in combination with chemotherapies, carboplatin, and either paclitaxel or nab-paclitaxel as a first-line treatment for patients with metastatic squamous non-small cell lung cancer (NSCLC). The results of the randomized trial showed an increase in overall survival, progression-free survival and overall response rate. Click here to read the full press release.
Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q and G719X may now take Gilotrif. Gilotrif, an oral, once-daily EGFR-directed therapy developed by Boehringer Ingelheim, is currently approved in the U.S. to treat people with NSCLC that has certain EGFR gene changes, has spread to other parts of the body [...]
Monday, November 6, 2017 - The United States Food and Drug Administration (FDA) approved Alecensa (alectinib) as a first treatment for advanced non-small cell lung cancer that is positive for a biomarker called ALK. Alecensa was already approved for ALK+ lung cancer that was resistant to other ALK-targeted therapies. Now, a large randomized clinical trial showed that Alecensa was more effective than previous first-line treatment. Patients had an average of 25.7 months without their cancer progressing (getting worse) when taking [...]